nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—CBR1—Doxorubicin—testicular cancer	0.259	0.349	CbGbCtD
Haloperidol—CYP3A7—Ifosfamide—testicular cancer	0.0665	0.0896	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.0665	0.0896	CbGbCtD
Haloperidol—CYP3A5—Ifosfamide—testicular cancer	0.0499	0.0672	CbGbCtD
Haloperidol—CYP2C19—Ifosfamide—testicular cancer	0.0402	0.0542	CbGbCtD
Haloperidol—CYP2C9—Ifosfamide—testicular cancer	0.0334	0.0451	CbGbCtD
Haloperidol—ABCB1—Dactinomycin—testicular cancer	0.0275	0.0371	CbGbCtD
Haloperidol—CYP3A5—Etoposide—testicular cancer	0.0238	0.0321	CbGbCtD
Haloperidol—CYP3A4—Ifosfamide—testicular cancer	0.0194	0.0262	CbGbCtD
Haloperidol—CYP1A2—Etoposide—testicular cancer	0.0177	0.0239	CbGbCtD
Haloperidol—ABCB1—Vinblastine—testicular cancer	0.0172	0.0232	CbGbCtD
Haloperidol—CYP2C9—Cisplatin—testicular cancer	0.0163	0.0219	CbGbCtD
Haloperidol—CYP2D6—Vinblastine—testicular cancer	0.0162	0.0219	CbGbCtD
Haloperidol—ABCB1—Cisplatin—testicular cancer	0.0158	0.0213	CbGbCtD
Haloperidol—ABCB1—Etoposide—testicular cancer	0.0155	0.0209	CbGbCtD
Haloperidol—ABCB1—Doxorubicin—testicular cancer	0.0106	0.0143	CbGbCtD
Haloperidol—CYP3A4—Vinblastine—testicular cancer	0.0103	0.0139	CbGbCtD
Haloperidol—ABCB1—Methotrexate—testicular cancer	0.0102	0.0138	CbGbCtD
Haloperidol—CYP2D6—Doxorubicin—testicular cancer	0.00997	0.0134	CbGbCtD
Haloperidol—H1F0—semen—testicular cancer	0.0095	0.199	CbGeAlD
Haloperidol—CYP3A4—Etoposide—testicular cancer	0.00929	0.0125	CbGbCtD
Haloperidol—CYP3A4—Doxorubicin—testicular cancer	0.00634	0.00855	CbGbCtD
Haloperidol—HTR2A—vein—testicular cancer	0.00436	0.0914	CbGeAlD
Haloperidol—CBR1—Vincristine—Vinblastine—testicular cancer	0.00405	1	CbGdCrCtD
Haloperidol—CBR1—seminal vesicle—testicular cancer	0.00246	0.0516	CbGeAlD
Haloperidol—H1F0—embryo—testicular cancer	0.00214	0.045	CbGeAlD
Haloperidol—DRD4—testis—testicular cancer	0.00206	0.0432	CbGeAlD
Haloperidol—H1F0—seminal vesicle—testicular cancer	0.00201	0.0422	CbGeAlD
Haloperidol—CBR1—gonad—testicular cancer	0.00178	0.0373	CbGeAlD
Haloperidol—CBR1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—testicular cancer	0.00162	0.197	CbGpPWpGaD
Haloperidol—H1F0—gonad—testicular cancer	0.00146	0.0305	CbGeAlD
Haloperidol—SIGMAR1—seminal vesicle—testicular cancer	0.00145	0.0305	CbGeAlD
Haloperidol—CBR1—female gonad—testicular cancer	0.00144	0.0303	CbGeAlD
Haloperidol—CBR1—testis—testicular cancer	0.00128	0.0269	CbGeAlD
Haloperidol—H1F0—female gonad—testicular cancer	0.00118	0.0248	CbGeAlD
Haloperidol—KCNH2—seminal vesicle—testicular cancer	0.00116	0.0243	CbGeAlD
Haloperidol—H1F0—testis—testicular cancer	0.00105	0.022	CbGeAlD
Haloperidol—CBR1—lymph node—testicular cancer	0.000928	0.0195	CbGeAlD
Haloperidol—SIGMAR1—female gonad—testicular cancer	0.000854	0.0179	CbGeAlD
Haloperidol—HTR2A—embryo—testicular cancer	0.000825	0.0173	CbGeAlD
Haloperidol—H1F0—lymph node—testicular cancer	0.00076	0.0159	CbGeAlD
Haloperidol—SIGMAR1—testis—testicular cancer	0.000757	0.0159	CbGeAlD
Haloperidol—CBR1—NRF2 pathway—SLC2A6—testicular cancer	0.000684	0.0833	CbGpPWpGaD
Haloperidol—KCNH2—female gonad—testicular cancer	0.00068	0.0143	CbGeAlD
Haloperidol—DRD2—testis—testicular cancer	0.000612	0.0128	CbGeAlD
Haloperidol—KCNH2—testis—testicular cancer	0.000603	0.0126	CbGeAlD
Haloperidol—CBR1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000585	0.0713	CbGpPWpGaD
Haloperidol—CYP1A1—female gonad—testicular cancer	0.000574	0.012	CbGeAlD
Haloperidol—CYP3A5—female gonad—testicular cancer	0.000561	0.0118	CbGeAlD
Haloperidol—HTR2A—gonad—testicular cancer	0.00056	0.0117	CbGeAlD
Haloperidol—SIGMAR1—lymph node—testicular cancer	0.000549	0.0115	CbGeAlD
Haloperidol—HTR2B—lymph node—testicular cancer	0.000548	0.0115	CbGeAlD
Haloperidol—HRH1—female gonad—testicular cancer	0.000545	0.0114	CbGeAlD
Haloperidol—ABCB1—embryo—testicular cancer	0.000541	0.0113	CbGeAlD
Haloperidol—ABCB1—seminal vesicle—testicular cancer	0.000508	0.0107	CbGeAlD
Haloperidol—HRH1—testis—testicular cancer	0.000483	0.0101	CbGeAlD
Haloperidol—KCNH2—lymph node—testicular cancer	0.000437	0.00917	CbGeAlD
Haloperidol—CYP2D6—female gonad—testicular cancer	0.000415	0.0087	CbGeAlD
Haloperidol—HTR2A—testis—testicular cancer	0.000404	0.00847	CbGeAlD
Haloperidol—CYP1A1—lymph node—testicular cancer	0.000369	0.00774	CbGeAlD
Haloperidol—CYP2D6—testis—testicular cancer	0.000368	0.00771	CbGeAlD
Haloperidol—ABCB1—gonad—testicular cancer	0.000367	0.0077	CbGeAlD
Haloperidol—HRH1—lymph node—testicular cancer	0.00035	0.00735	CbGeAlD
Haloperidol—Hyperhidrosis—Cisplatin—testicular cancer	0.000307	0.00154	CcSEcCtD
Haloperidol—Liver function test abnormal—Epirubicin—testicular cancer	0.000306	0.00154	CcSEcCtD
Haloperidol—Pruritus—Bleomycin—testicular cancer	0.000304	0.00153	CcSEcCtD
Haloperidol—Feeling abnormal—Ifosfamide—testicular cancer	0.000303	0.00153	CcSEcCtD
Haloperidol—Nausea—Vinblastine—testicular cancer	0.000303	0.00152	CcSEcCtD
Haloperidol—Orthostatic hypotension—Epirubicin—testicular cancer	0.000303	0.00152	CcSEcCtD
Haloperidol—Anorexia—Cisplatin—testicular cancer	0.000302	0.00152	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000301	0.00151	CcSEcCtD
Haloperidol—Breast disorder—Epirubicin—testicular cancer	0.000299	0.00151	CcSEcCtD
Haloperidol—ABCB1—female gonad—testicular cancer	0.000298	0.00625	CbGeAlD
Haloperidol—Hypotension—Cisplatin—testicular cancer	0.000296	0.00149	CcSEcCtD
Haloperidol—Face oedema—Doxorubicin—testicular cancer	0.000296	0.00149	CcSEcCtD
Haloperidol—Hypersensitivity—Dactinomycin—testicular cancer	0.000296	0.00149	CcSEcCtD
Haloperidol—Confusional state—Etoposide—testicular cancer	0.000293	0.00147	CcSEcCtD
Haloperidol—Urticaria—Ifosfamide—testicular cancer	0.000292	0.00147	CcSEcCtD
Haloperidol—Cardiac arrest—Doxorubicin—testicular cancer	0.000292	0.00147	CcSEcCtD
Haloperidol—Body temperature increased—Ifosfamide—testicular cancer	0.000291	0.00146	CcSEcCtD
Haloperidol—Pancytopenia—Methotrexate—testicular cancer	0.000291	0.00146	CcSEcCtD
Haloperidol—Anaphylactic shock—Etoposide—testicular cancer	0.000291	0.00146	CcSEcCtD
Haloperidol—Dysphagia—Epirubicin—testicular cancer	0.000286	0.00144	CcSEcCtD
Haloperidol—Neutropenia—Methotrexate—testicular cancer	0.000286	0.00144	CcSEcCtD
Haloperidol—Thrombocytopenia—Etoposide—testicular cancer	0.000284	0.00143	CcSEcCtD
Haloperidol—Tachycardia—Etoposide—testicular cancer	0.000284	0.00143	CcSEcCtD
Haloperidol—Liver function test abnormal—Doxorubicin—testicular cancer	0.000283	0.00142	CcSEcCtD
Haloperidol—Dyspnoea—Cisplatin—testicular cancer	0.000283	0.00142	CcSEcCtD
Haloperidol—Skin disorder—Etoposide—testicular cancer	0.000282	0.00142	CcSEcCtD
Haloperidol—Erectile dysfunction—Methotrexate—testicular cancer	0.000282	0.00142	CcSEcCtD
Haloperidol—Hyperhidrosis—Etoposide—testicular cancer	0.000281	0.00141	CcSEcCtD
Haloperidol—Orthostatic hypotension—Doxorubicin—testicular cancer	0.00028	0.00141	CcSEcCtD
Haloperidol—Photosensitivity reaction—Methotrexate—testicular cancer	0.000279	0.00141	CcSEcCtD
Haloperidol—Breast disorder—Doxorubicin—testicular cancer	0.000277	0.00139	CcSEcCtD
Haloperidol—Anorexia—Etoposide—testicular cancer	0.000277	0.00139	CcSEcCtD
Haloperidol—Decreased appetite—Cisplatin—testicular cancer	0.000276	0.00139	CcSEcCtD
Haloperidol—Diarrhoea—Dactinomycin—testicular cancer	0.000275	0.00138	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000274	0.00138	CcSEcCtD
Haloperidol—Vomiting—Bleomycin—testicular cancer	0.000274	0.00138	CcSEcCtD
Haloperidol—Drowsiness—Methotrexate—testicular cancer	0.000273	0.00137	CcSEcCtD
Haloperidol—Depression—Methotrexate—testicular cancer	0.000272	0.00137	CcSEcCtD
Haloperidol—Pancytopenia—Epirubicin—testicular cancer	0.000272	0.00137	CcSEcCtD
Haloperidol—Hypotension—Etoposide—testicular cancer	0.000271	0.00137	CcSEcCtD
Haloperidol—Rash—Bleomycin—testicular cancer	0.000271	0.00137	CcSEcCtD
Haloperidol—Dermatitis—Bleomycin—testicular cancer	0.000271	0.00136	CcSEcCtD
Haloperidol—Hypersensitivity—Ifosfamide—testicular cancer	0.000271	0.00136	CcSEcCtD
Haloperidol—Neutropenia—Epirubicin—testicular cancer	0.000268	0.00135	CcSEcCtD
Haloperidol—Dysphagia—Doxorubicin—testicular cancer	0.000265	0.00133	CcSEcCtD
Haloperidol—ABCB1—testis—testicular cancer	0.000264	0.00555	CbGeAlD
Haloperidol—Photosensitivity reaction—Epirubicin—testicular cancer	0.000261	0.00132	CcSEcCtD
Haloperidol—Feeling abnormal—Cisplatin—testicular cancer	0.000261	0.00132	CcSEcCtD
Haloperidol—Weight increased—Epirubicin—testicular cancer	0.000261	0.00131	CcSEcCtD
Haloperidol—Pruritus—Ifosfamide—testicular cancer	0.00026	0.00131	CcSEcCtD
Haloperidol—Weight decreased—Epirubicin—testicular cancer	0.000259	0.0013	CcSEcCtD
Haloperidol—Dyspnoea—Etoposide—testicular cancer	0.000259	0.0013	CcSEcCtD
Haloperidol—Hyperglycaemia—Epirubicin—testicular cancer	0.000258	0.0013	CcSEcCtD
Haloperidol—Somnolence—Etoposide—testicular cancer	0.000258	0.0013	CcSEcCtD
Haloperidol—Hepatobiliary disease—Methotrexate—testicular cancer	0.000258	0.0013	CcSEcCtD
Haloperidol—Nausea—Bleomycin—testicular cancer	0.000256	0.00129	CcSEcCtD
Haloperidol—Drowsiness—Epirubicin—testicular cancer	0.000255	0.00129	CcSEcCtD
Haloperidol—Vomiting—Dactinomycin—testicular cancer	0.000255	0.00128	CcSEcCtD
Haloperidol—Agranulocytosis—Methotrexate—testicular cancer	0.000255	0.00128	CcSEcCtD
Haloperidol—Rash—Dactinomycin—testicular cancer	0.000253	0.00127	CcSEcCtD
Haloperidol—Decreased appetite—Etoposide—testicular cancer	0.000253	0.00127	CcSEcCtD
Haloperidol—Diarrhoea—Ifosfamide—testicular cancer	0.000252	0.00127	CcSEcCtD
Haloperidol—Pancytopenia—Doxorubicin—testicular cancer	0.000252	0.00127	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Etoposide—testicular cancer	0.000251	0.00126	CcSEcCtD
Haloperidol—Body temperature increased—Cisplatin—testicular cancer	0.000251	0.00126	CcSEcCtD
Haloperidol—Jaundice—Epirubicin—testicular cancer	0.000249	0.00125	CcSEcCtD
Haloperidol—Constipation—Etoposide—testicular cancer	0.000248	0.00125	CcSEcCtD
Haloperidol—Neutropenia—Doxorubicin—testicular cancer	0.000248	0.00125	CcSEcCtD
Haloperidol—Hepatitis—Methotrexate—testicular cancer	0.000245	0.00123	CcSEcCtD
Haloperidol—Dizziness—Ifosfamide—testicular cancer	0.000243	0.00122	CcSEcCtD
Haloperidol—Urinary tract disorder—Methotrexate—testicular cancer	0.000242	0.00122	CcSEcCtD
Haloperidol—Photosensitivity reaction—Doxorubicin—testicular cancer	0.000242	0.00122	CcSEcCtD
Haloperidol—Hepatobiliary disease—Epirubicin—testicular cancer	0.000241	0.00122	CcSEcCtD
Haloperidol—Weight increased—Doxorubicin—testicular cancer	0.000241	0.00121	CcSEcCtD
Haloperidol—Urethral disorder—Methotrexate—testicular cancer	0.00024	0.00121	CcSEcCtD
Haloperidol—Weight decreased—Doxorubicin—testicular cancer	0.00024	0.00121	CcSEcCtD
Haloperidol—Feeling abnormal—Etoposide—testicular cancer	0.000239	0.00121	CcSEcCtD
Haloperidol—Hyperglycaemia—Doxorubicin—testicular cancer	0.000239	0.0012	CcSEcCtD
Haloperidol—Nausea—Dactinomycin—testicular cancer	0.000238	0.0012	CcSEcCtD
Haloperidol—Agranulocytosis—Epirubicin—testicular cancer	0.000238	0.0012	CcSEcCtD
Haloperidol—Drowsiness—Doxorubicin—testicular cancer	0.000236	0.00119	CcSEcCtD
Haloperidol—Visual impairment—Methotrexate—testicular cancer	0.000236	0.00119	CcSEcCtD
Haloperidol—Vomiting—Ifosfamide—testicular cancer	0.000234	0.00118	CcSEcCtD
Haloperidol—Hypersensitivity—Cisplatin—testicular cancer	0.000234	0.00118	CcSEcCtD
Haloperidol—H1F0—DNA Damage/Telomere Stress Induced Senescence—H2AFZ—testicular cancer	0.000234	0.0285	CbGpPWpGaD
Haloperidol—Rash—Ifosfamide—testicular cancer	0.000232	0.00117	CcSEcCtD
Haloperidol—Dermatitis—Ifosfamide—testicular cancer	0.000232	0.00117	CcSEcCtD
Haloperidol—Urticaria—Etoposide—testicular cancer	0.000231	0.00116	CcSEcCtD
Haloperidol—Jaundice—Doxorubicin—testicular cancer	0.00023	0.00116	CcSEcCtD
Haloperidol—Body temperature increased—Etoposide—testicular cancer	0.00023	0.00116	CcSEcCtD
Haloperidol—Hepatitis—Epirubicin—testicular cancer	0.000229	0.00115	CcSEcCtD
Haloperidol—Eye disorder—Methotrexate—testicular cancer	0.000229	0.00115	CcSEcCtD
Haloperidol—Cardiac disorder—Methotrexate—testicular cancer	0.000227	0.00114	CcSEcCtD
Haloperidol—Urinary tract disorder—Epirubicin—testicular cancer	0.000226	0.00114	CcSEcCtD
Haloperidol—Connective tissue disorder—Epirubicin—testicular cancer	0.000225	0.00113	CcSEcCtD
Haloperidol—Urethral disorder—Epirubicin—testicular cancer	0.000225	0.00113	CcSEcCtD
Haloperidol—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000223	0.00112	CcSEcCtD
Haloperidol—Angiopathy—Methotrexate—testicular cancer	0.000222	0.00112	CcSEcCtD
Haloperidol—Immune system disorder—Methotrexate—testicular cancer	0.000221	0.00111	CcSEcCtD
Haloperidol—Visual impairment—Epirubicin—testicular cancer	0.000221	0.00111	CcSEcCtD
Haloperidol—Mediastinal disorder—Methotrexate—testicular cancer	0.000221	0.00111	CcSEcCtD
Haloperidol—Agranulocytosis—Doxorubicin—testicular cancer	0.00022	0.00111	CcSEcCtD
Haloperidol—Nausea—Ifosfamide—testicular cancer	0.000218	0.0011	CcSEcCtD
Haloperidol—Diarrhoea—Cisplatin—testicular cancer	0.000217	0.00109	CcSEcCtD
Haloperidol—Alopecia—Methotrexate—testicular cancer	0.000216	0.00109	CcSEcCtD
Haloperidol—Mental disorder—Methotrexate—testicular cancer	0.000215	0.00108	CcSEcCtD
Haloperidol—Eye disorder—Epirubicin—testicular cancer	0.000214	0.00108	CcSEcCtD
Haloperidol—Hypersensitivity—Etoposide—testicular cancer	0.000214	0.00108	CcSEcCtD
Haloperidol—Malnutrition—Methotrexate—testicular cancer	0.000213	0.00107	CcSEcCtD
Haloperidol—Cardiac disorder—Epirubicin—testicular cancer	0.000213	0.00107	CcSEcCtD
Haloperidol—Hepatitis—Doxorubicin—testicular cancer	0.000212	0.00107	CcSEcCtD
Haloperidol—Urinary tract disorder—Doxorubicin—testicular cancer	0.000209	0.00105	CcSEcCtD
Haloperidol—Connective tissue disorder—Doxorubicin—testicular cancer	0.000208	0.00105	CcSEcCtD
Haloperidol—Angiopathy—Epirubicin—testicular cancer	0.000208	0.00105	CcSEcCtD
Haloperidol—Urethral disorder—Doxorubicin—testicular cancer	0.000208	0.00105	CcSEcCtD
Haloperidol—Immune system disorder—Epirubicin—testicular cancer	0.000207	0.00104	CcSEcCtD
Haloperidol—Mediastinal disorder—Epirubicin—testicular cancer	0.000207	0.00104	CcSEcCtD
Haloperidol—UGT1A9—NRF2 pathway—SLC2A6—testicular cancer	0.000206	0.0251	CbGpPWpGaD
Haloperidol—Pruritus—Etoposide—testicular cancer	0.000206	0.00103	CcSEcCtD
Haloperidol—Visual impairment—Doxorubicin—testicular cancer	0.000204	0.00103	CcSEcCtD
Haloperidol—Alopecia—Epirubicin—testicular cancer	0.000203	0.00102	CcSEcCtD
Haloperidol—Vomiting—Cisplatin—testicular cancer	0.000202	0.00101	CcSEcCtD
Haloperidol—Vision blurred—Methotrexate—testicular cancer	0.000201	0.00101	CcSEcCtD
Haloperidol—Mental disorder—Epirubicin—testicular cancer	0.000201	0.00101	CcSEcCtD
Haloperidol—Rash—Cisplatin—testicular cancer	0.0002	0.00101	CcSEcCtD
Haloperidol—Dermatitis—Cisplatin—testicular cancer	0.0002	0.00101	CcSEcCtD
Haloperidol—Malnutrition—Epirubicin—testicular cancer	0.0002	0.001	CcSEcCtD
Haloperidol—Diarrhoea—Etoposide—testicular cancer	0.000199	0.001	CcSEcCtD
Haloperidol—Eye disorder—Doxorubicin—testicular cancer	0.000198	0.000998	CcSEcCtD
Haloperidol—Anaemia—Methotrexate—testicular cancer	0.000197	0.000992	CcSEcCtD
Haloperidol—Cardiac disorder—Doxorubicin—testicular cancer	0.000197	0.000991	CcSEcCtD
Haloperidol—Angiopathy—Doxorubicin—testicular cancer	0.000192	0.000969	CcSEcCtD
Haloperidol—Dizziness—Etoposide—testicular cancer	0.000192	0.000967	CcSEcCtD
Haloperidol—Muscle spasms—Epirubicin—testicular cancer	0.000192	0.000966	CcSEcCtD
Haloperidol—ABCB1—lymph node—testicular cancer	0.000192	0.00402	CbGeAlD
Haloperidol—Immune system disorder—Doxorubicin—testicular cancer	0.000192	0.000964	CcSEcCtD
Haloperidol—Vertigo—Methotrexate—testicular cancer	0.000192	0.000964	CcSEcCtD
Haloperidol—Mediastinal disorder—Doxorubicin—testicular cancer	0.000191	0.000962	CcSEcCtD
Haloperidol—Leukopenia—Methotrexate—testicular cancer	0.000191	0.000961	CcSEcCtD
Haloperidol—DRD1—G alpha (s) signalling events—INSL3—testicular cancer	0.000191	0.0232	CbGpPWpGaD
Haloperidol—KCNH2—Hematopoietic Stem Cell Differentiation—KITLG—testicular cancer	0.00019	0.0232	CbGpPWpGaD
Haloperidol—Nausea—Cisplatin—testicular cancer	0.000188	0.000948	CcSEcCtD
Haloperidol—Vision blurred—Epirubicin—testicular cancer	0.000188	0.000947	CcSEcCtD
Haloperidol—Alopecia—Doxorubicin—testicular cancer	0.000187	0.000943	CcSEcCtD
Haloperidol—Mental disorder—Doxorubicin—testicular cancer	0.000186	0.000935	CcSEcCtD
Haloperidol—Convulsion—Methotrexate—testicular cancer	0.000185	0.00093	CcSEcCtD
Haloperidol—Vomiting—Etoposide—testicular cancer	0.000185	0.00093	CcSEcCtD
Haloperidol—Malnutrition—Doxorubicin—testicular cancer	0.000185	0.000929	CcSEcCtD
Haloperidol—Anaemia—Epirubicin—testicular cancer	0.000184	0.000928	CcSEcCtD
Haloperidol—Agitation—Epirubicin—testicular cancer	0.000183	0.000923	CcSEcCtD
Haloperidol—Rash—Etoposide—testicular cancer	0.000183	0.000922	CcSEcCtD
Haloperidol—Dermatitis—Etoposide—testicular cancer	0.000183	0.000921	CcSEcCtD
Haloperidol—Headache—Etoposide—testicular cancer	0.000182	0.000916	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00018	0.000907	CcSEcCtD
Haloperidol—Vertigo—Epirubicin—testicular cancer	0.000179	0.000902	CcSEcCtD
Haloperidol—Leukopenia—Epirubicin—testicular cancer	0.000179	0.000899	CcSEcCtD
Haloperidol—Muscle spasms—Doxorubicin—testicular cancer	0.000177	0.000893	CcSEcCtD
Haloperidol—Confusional state—Methotrexate—testicular cancer	0.000175	0.000883	CcSEcCtD
Haloperidol—Anaphylactic shock—Methotrexate—testicular cancer	0.000174	0.000876	CcSEcCtD
Haloperidol—Vision blurred—Doxorubicin—testicular cancer	0.000174	0.000876	CcSEcCtD
Haloperidol—Convulsion—Epirubicin—testicular cancer	0.000173	0.00087	CcSEcCtD
Haloperidol—Nausea—Etoposide—testicular cancer	0.000173	0.000869	CcSEcCtD
Haloperidol—Hypertension—Epirubicin—testicular cancer	0.000172	0.000867	CcSEcCtD
Haloperidol—Nervous system disorder—Methotrexate—testicular cancer	0.000171	0.000859	CcSEcCtD
Haloperidol—Anaemia—Doxorubicin—testicular cancer	0.000171	0.000859	CcSEcCtD
Haloperidol—Thrombocytopenia—Methotrexate—testicular cancer	0.00017	0.000858	CcSEcCtD
Haloperidol—Agitation—Doxorubicin—testicular cancer	0.00017	0.000854	CcSEcCtD
Haloperidol—Anxiety—Epirubicin—testicular cancer	0.000169	0.000852	CcSEcCtD
Haloperidol—Skin disorder—Methotrexate—testicular cancer	0.000169	0.000851	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000169	0.000849	CcSEcCtD
Haloperidol—Hyperhidrosis—Methotrexate—testicular cancer	0.000168	0.000847	CcSEcCtD
Haloperidol—Dry mouth—Epirubicin—testicular cancer	0.000166	0.000836	CcSEcCtD
Haloperidol—Vertigo—Doxorubicin—testicular cancer	0.000166	0.000835	CcSEcCtD
Haloperidol—Anorexia—Methotrexate—testicular cancer	0.000166	0.000835	CcSEcCtD
Haloperidol—Leukopenia—Doxorubicin—testicular cancer	0.000165	0.000832	CcSEcCtD
Haloperidol—Confusional state—Epirubicin—testicular cancer	0.000164	0.000827	CcSEcCtD
Haloperidol—Oedema—Epirubicin—testicular cancer	0.000163	0.00082	CcSEcCtD
Haloperidol—Anaphylactic shock—Epirubicin—testicular cancer	0.000163	0.00082	CcSEcCtD
Haloperidol—Hypotension—Methotrexate—testicular cancer	0.000163	0.000818	CcSEcCtD
Haloperidol—Convulsion—Doxorubicin—testicular cancer	0.00016	0.000805	CcSEcCtD
Haloperidol—Nervous system disorder—Epirubicin—testicular cancer	0.00016	0.000804	CcSEcCtD
Haloperidol—Thrombocytopenia—Epirubicin—testicular cancer	0.000159	0.000803	CcSEcCtD
Haloperidol—Hypertension—Doxorubicin—testicular cancer	0.000159	0.000802	CcSEcCtD
Haloperidol—Tachycardia—Epirubicin—testicular cancer	0.000159	0.0008	CcSEcCtD
Haloperidol—Skin disorder—Epirubicin—testicular cancer	0.000158	0.000796	CcSEcCtD
Haloperidol—Hyperhidrosis—Epirubicin—testicular cancer	0.000157	0.000792	CcSEcCtD
Haloperidol—Insomnia—Methotrexate—testicular cancer	0.000157	0.000792	CcSEcCtD
Haloperidol—Anxiety—Doxorubicin—testicular cancer	0.000157	0.000788	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000156	0.000786	CcSEcCtD
Haloperidol—Anorexia—Epirubicin—testicular cancer	0.000155	0.000781	CcSEcCtD
Haloperidol—Dyspnoea—Methotrexate—testicular cancer	0.000155	0.000781	CcSEcCtD
Haloperidol—Somnolence—Methotrexate—testicular cancer	0.000155	0.000779	CcSEcCtD
Haloperidol—Dry mouth—Doxorubicin—testicular cancer	0.000154	0.000774	CcSEcCtD
Haloperidol—Dyspepsia—Methotrexate—testicular cancer	0.000153	0.000771	CcSEcCtD
Haloperidol—Hypotension—Epirubicin—testicular cancer	0.000152	0.000766	CcSEcCtD
Haloperidol—Confusional state—Doxorubicin—testicular cancer	0.000152	0.000765	CcSEcCtD
Haloperidol—Decreased appetite—Methotrexate—testicular cancer	0.000151	0.000761	CcSEcCtD
Haloperidol—Anaphylactic shock—Doxorubicin—testicular cancer	0.000151	0.000758	CcSEcCtD
Haloperidol—Oedema—Doxorubicin—testicular cancer	0.000151	0.000758	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00015	0.000756	CcSEcCtD
Haloperidol—GRIN2B—Developmental Biology—PRDM14—testicular cancer	0.00015	0.0183	CbGpPWpGaD
Haloperidol—Nervous system disorder—Doxorubicin—testicular cancer	0.000148	0.000744	CcSEcCtD
Haloperidol—Thrombocytopenia—Doxorubicin—testicular cancer	0.000148	0.000743	CcSEcCtD
Haloperidol—Insomnia—Epirubicin—testicular cancer	0.000147	0.000741	CcSEcCtD
Haloperidol—Tachycardia—Doxorubicin—testicular cancer	0.000147	0.00074	CcSEcCtD
Haloperidol—Skin disorder—Doxorubicin—testicular cancer	0.000146	0.000737	CcSEcCtD
Haloperidol—Hyperhidrosis—Doxorubicin—testicular cancer	0.000146	0.000733	CcSEcCtD
Haloperidol—Dyspnoea—Epirubicin—testicular cancer	0.000145	0.000731	CcSEcCtD
Haloperidol—Somnolence—Epirubicin—testicular cancer	0.000145	0.000729	CcSEcCtD
Haloperidol—Anorexia—Doxorubicin—testicular cancer	0.000144	0.000723	CcSEcCtD
Haloperidol—Feeling abnormal—Methotrexate—testicular cancer	0.000143	0.000722	CcSEcCtD
Haloperidol—Dyspepsia—Epirubicin—testicular cancer	0.000143	0.000722	CcSEcCtD
Haloperidol—Decreased appetite—Epirubicin—testicular cancer	0.000142	0.000713	CcSEcCtD
Haloperidol—Hypotension—Doxorubicin—testicular cancer	0.000141	0.000709	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000141	0.000708	CcSEcCtD
Haloperidol—Constipation—Epirubicin—testicular cancer	0.000139	0.000701	CcSEcCtD
Haloperidol—Urticaria—Methotrexate—testicular cancer	0.000138	0.000696	CcSEcCtD
Haloperidol—Body temperature increased—Methotrexate—testicular cancer	0.000138	0.000692	CcSEcCtD
Haloperidol—Insomnia—Doxorubicin—testicular cancer	0.000136	0.000686	CcSEcCtD
Haloperidol—Dyspnoea—Doxorubicin—testicular cancer	0.000134	0.000676	CcSEcCtD
Haloperidol—Feeling abnormal—Epirubicin—testicular cancer	0.000134	0.000675	CcSEcCtD
Haloperidol—Somnolence—Doxorubicin—testicular cancer	0.000134	0.000674	CcSEcCtD
Haloperidol—Dyspepsia—Doxorubicin—testicular cancer	0.000133	0.000668	CcSEcCtD
Haloperidol—Decreased appetite—Doxorubicin—testicular cancer	0.000131	0.000659	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.00013	0.000655	CcSEcCtD
Haloperidol—Urticaria—Epirubicin—testicular cancer	0.000129	0.000651	CcSEcCtD
Haloperidol—Constipation—Doxorubicin—testicular cancer	0.000129	0.000649	CcSEcCtD
Haloperidol—Body temperature increased—Epirubicin—testicular cancer	0.000129	0.000648	CcSEcCtD
Haloperidol—Hypersensitivity—Methotrexate—testicular cancer	0.000128	0.000645	CcSEcCtD
Haloperidol—Feeling abnormal—Doxorubicin—testicular cancer	0.000124	0.000625	CcSEcCtD
Haloperidol—Pruritus—Methotrexate—testicular cancer	0.000123	0.00062	CcSEcCtD
Haloperidol—Hypersensitivity—Epirubicin—testicular cancer	0.00012	0.000604	CcSEcCtD
Haloperidol—Urticaria—Doxorubicin—testicular cancer	0.00012	0.000603	CcSEcCtD
Haloperidol—Body temperature increased—Doxorubicin—testicular cancer	0.000119	0.0006	CcSEcCtD
Haloperidol—Diarrhoea—Methotrexate—testicular cancer	0.000119	0.000599	CcSEcCtD
Haloperidol—Pruritus—Epirubicin—testicular cancer	0.000115	0.00058	CcSEcCtD
Haloperidol—Dizziness—Methotrexate—testicular cancer	0.000115	0.000579	CcSEcCtD
Haloperidol—H1F0—Cellular Senescence—H2AFZ—testicular cancer	0.000114	0.0139	CbGpPWpGaD
Haloperidol—UGT1A9—Phase II conjugation—HPGDS—testicular cancer	0.000112	0.0136	CbGpPWpGaD
Haloperidol—Diarrhoea—Epirubicin—testicular cancer	0.000111	0.000561	CcSEcCtD
Haloperidol—Hypersensitivity—Doxorubicin—testicular cancer	0.000111	0.000559	CcSEcCtD
Haloperidol—Vomiting—Methotrexate—testicular cancer	0.000111	0.000557	CcSEcCtD
Haloperidol—Rash—Methotrexate—testicular cancer	0.00011	0.000552	CcSEcCtD
Haloperidol—Dermatitis—Methotrexate—testicular cancer	0.00011	0.000552	CcSEcCtD
Haloperidol—Headache—Methotrexate—testicular cancer	0.000109	0.000549	CcSEcCtD
Haloperidol—CYP1A1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000108	0.0132	CbGpPWpGaD
Haloperidol—Dizziness—Epirubicin—testicular cancer	0.000108	0.000542	CcSEcCtD
Haloperidol—Pruritus—Doxorubicin—testicular cancer	0.000107	0.000537	CcSEcCtD
Haloperidol—HTR1D—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000105	0.0128	CbGpPWpGaD
Haloperidol—Vomiting—Epirubicin—testicular cancer	0.000104	0.000521	CcSEcCtD
Haloperidol—Nausea—Methotrexate—testicular cancer	0.000103	0.00052	CcSEcCtD
Haloperidol—Diarrhoea—Doxorubicin—testicular cancer	0.000103	0.000519	CcSEcCtD
Haloperidol—Rash—Epirubicin—testicular cancer	0.000103	0.000517	CcSEcCtD
Haloperidol—Dermatitis—Epirubicin—testicular cancer	0.000103	0.000516	CcSEcCtD
Haloperidol—HTR1B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000103	0.0125	CbGpPWpGaD
Haloperidol—Headache—Epirubicin—testicular cancer	0.000102	0.000514	CcSEcCtD
Haloperidol—CYP1A1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000101	0.0123	CbGpPWpGaD
Haloperidol—DRD4—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000101	0.0123	CbGpPWpGaD
Haloperidol—Dizziness—Doxorubicin—testicular cancer	9.96e-05	0.000502	CcSEcCtD
Haloperidol—Nausea—Epirubicin—testicular cancer	9.67e-05	0.000487	CcSEcCtD
Haloperidol—HTR2B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	9.64e-05	0.0117	CbGpPWpGaD
Haloperidol—Vomiting—Doxorubicin—testicular cancer	9.58e-05	0.000482	CcSEcCtD
Haloperidol—Rash—Doxorubicin—testicular cancer	9.5e-05	0.000478	CcSEcCtD
Haloperidol—Dermatitis—Doxorubicin—testicular cancer	9.49e-05	0.000478	CcSEcCtD
Haloperidol—Headache—Doxorubicin—testicular cancer	9.44e-05	0.000475	CcSEcCtD
Haloperidol—DRD1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	9.09e-05	0.0111	CbGpPWpGaD
Haloperidol—DRD3—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	8.97e-05	0.0109	CbGpPWpGaD
Haloperidol—Nausea—Doxorubicin—testicular cancer	8.95e-05	0.000451	CcSEcCtD
Haloperidol—H1F0—Cellular responses to stress—H2AFZ—testicular cancer	8.63e-05	0.0105	CbGpPWpGaD
Haloperidol—EBP—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	8.5e-05	0.0104	CbGpPWpGaD
Haloperidol—CBR1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	8.36e-05	0.0102	CbGpPWpGaD
Haloperidol—CYP2C19—Arachidonic acid metabolism—HPGDS—testicular cancer	8.27e-05	0.0101	CbGpPWpGaD
Haloperidol—HTR1D—GPCR ligand binding—INSL3—testicular cancer	7.98e-05	0.00972	CbGpPWpGaD
Haloperidol—HTR1B—GPCR ligand binding—INSL3—testicular cancer	7.81e-05	0.00952	CbGpPWpGaD
Haloperidol—DRD4—GPCR ligand binding—INSL3—testicular cancer	7.69e-05	0.00937	CbGpPWpGaD
Haloperidol—CYP2C9—Arachidonic acid metabolism—HPGDS—testicular cancer	7.54e-05	0.00919	CbGpPWpGaD
Haloperidol—HTR2B—GPCR ligand binding—INSL3—testicular cancer	7.34e-05	0.00894	CbGpPWpGaD
Haloperidol—DRD1—GPCR ligand binding—INSL3—testicular cancer	6.92e-05	0.00843	CbGpPWpGaD
Haloperidol—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	6.89e-05	0.00839	CbGpPWpGaD
Haloperidol—DRD2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	6.86e-05	0.00836	CbGpPWpGaD
Haloperidol—DRD3—GPCR ligand binding—INSL3—testicular cancer	6.83e-05	0.00832	CbGpPWpGaD
Haloperidol—GRIN2B—EPH-Ephrin signaling—MMP2—testicular cancer	6.79e-05	0.00828	CbGpPWpGaD
Haloperidol—HTR2A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	6.75e-05	0.00823	CbGpPWpGaD
Haloperidol—HRH1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	6.74e-05	0.00821	CbGpPWpGaD
Haloperidol—UGT1A9—Biological oxidations—HPGDS—testicular cancer	6.55e-05	0.00798	CbGpPWpGaD
Haloperidol—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	6.44e-05	0.00785	CbGpPWpGaD
Haloperidol—CYP3A7—Biological oxidations—HPGDS—testicular cancer	5.51e-05	0.00671	CbGpPWpGaD
Haloperidol—DRD2—GPCR ligand binding—INSL3—testicular cancer	5.22e-05	0.00637	CbGpPWpGaD
Haloperidol—HTR2A—GPCR ligand binding—INSL3—testicular cancer	5.14e-05	0.00626	CbGpPWpGaD
Haloperidol—HRH1—GPCR ligand binding—INSL3—testicular cancer	5.13e-05	0.00625	CbGpPWpGaD
Haloperidol—HTR1D—GPCR downstream signaling—INSL3—testicular cancer	4.51e-05	0.00549	CbGpPWpGaD
Haloperidol—HTR1B—GPCR downstream signaling—INSL3—testicular cancer	4.41e-05	0.00538	CbGpPWpGaD
Haloperidol—DRD4—GPCR downstream signaling—INSL3—testicular cancer	4.34e-05	0.00529	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—INSL3—testicular cancer	4.15e-05	0.00505	CbGpPWpGaD
Haloperidol—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	4.1e-05	0.00499	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—INSL3—testicular cancer	4.09e-05	0.00499	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—INSL3—testicular cancer	4.01e-05	0.00489	CbGpPWpGaD
Haloperidol—CYP3A5—Biological oxidations—HPGDS—testicular cancer	3.98e-05	0.00485	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—INSL3—testicular cancer	3.94e-05	0.00481	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—INSL3—testicular cancer	3.91e-05	0.00477	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—INSL3—testicular cancer	3.86e-05	0.0047	CbGpPWpGaD
Haloperidol—EBP—Metabolism—HPGDS—testicular cancer	3.78e-05	0.00461	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—INSL3—testicular cancer	3.77e-05	0.00459	CbGpPWpGaD
Haloperidol—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	3.76e-05	0.00458	CbGpPWpGaD
Haloperidol—CYP1A1—Biological oxidations—HPGDS—testicular cancer	3.76e-05	0.00458	CbGpPWpGaD
Haloperidol—CBR1—Metabolism—HPGDS—testicular cancer	3.72e-05	0.00454	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—INSL3—testicular cancer	3.55e-05	0.00433	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—INSL3—testicular cancer	3.5e-05	0.00427	CbGpPWpGaD
Haloperidol—CYP2C19—Biological oxidations—HPGDS—testicular cancer	3.08e-05	0.00375	CbGpPWpGaD
Haloperidol—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.02e-05	0.00368	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—INSL3—testicular cancer	2.95e-05	0.0036	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—INSL3—testicular cancer	2.9e-05	0.00354	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—INSL3—testicular cancer	2.9e-05	0.00353	CbGpPWpGaD
Haloperidol—CYP2D6—Biological oxidations—HPGDS—testicular cancer	2.83e-05	0.00345	CbGpPWpGaD
Haloperidol—CYP2C9—Biological oxidations—HPGDS—testicular cancer	2.81e-05	0.00342	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	2.76e-05	0.00337	CbGpPWpGaD
Haloperidol—EBP—Metabolism—STK11—testicular cancer	2.75e-05	0.00335	CbGpPWpGaD
Haloperidol—CBR1—Metabolism—STK11—testicular cancer	2.7e-05	0.0033	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—INSL3—testicular cancer	2.68e-05	0.00327	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—INSL3—testicular cancer	2.64e-05	0.00321	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—INSL3—testicular cancer	2.63e-05	0.00321	CbGpPWpGaD
Haloperidol—GRIN2B—Axon guidance—MMP2—testicular cancer	2.52e-05	0.00308	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.51e-05	0.00306	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—INSL3—testicular cancer	2.42e-05	0.00295	CbGpPWpGaD
Haloperidol—CYP1A2—Biological oxidations—HPGDS—testicular cancer	2.4e-05	0.00292	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—INSL3—testicular cancer	2.37e-05	0.00289	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—INSL3—testicular cancer	2.33e-05	0.00284	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—INSL3—testicular cancer	2.22e-05	0.00271	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—INSL3—testicular cancer	2.1e-05	0.00256	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—INSL3—testicular cancer	2.07e-05	0.00252	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	2.01e-05	0.00245	CbGpPWpGaD
Haloperidol—CYP3A4—Biological oxidations—HPGDS—testicular cancer	1.85e-05	0.00225	CbGpPWpGaD
Haloperidol—GRIN2B—Developmental Biology—MMP2—testicular cancer	1.8e-05	0.0022	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—INSL3—testicular cancer	1.58e-05	0.00193	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—INSL3—testicular cancer	1.56e-05	0.0019	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—INSL3—testicular cancer	1.55e-05	0.0019	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.44e-05	0.00176	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.18e-05	0.00144	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—HPGDS—testicular cancer	1.12e-05	0.00136	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.08e-05	0.00131	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—HPGDS—testicular cancer	9.42e-06	0.00115	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	9.21e-06	0.00112	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—STK11—testicular cancer	8.13e-06	0.000991	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—H2AFZ—testicular cancer	7.74e-06	0.000943	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—STK11—testicular cancer	7.7e-06	0.000938	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—H2AFZ—testicular cancer	7.58e-06	0.000924	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—STK11—testicular cancer	7.54e-06	0.000918	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—H2AFZ—testicular cancer	7.46e-06	0.000909	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—STK11—testicular cancer	7.42e-06	0.000904	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—KITLG—testicular cancer	7.12e-06	0.000868	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—H2AFZ—testicular cancer	7.12e-06	0.000868	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—STK11—testicular cancer	7.08e-06	0.000863	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—KITLG—testicular cancer	6.97e-06	0.00085	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—KITLG—testicular cancer	6.86e-06	0.000836	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—STK11—testicular cancer	6.84e-06	0.000834	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—HPGDS—testicular cancer	6.81e-06	0.000829	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—H2AFZ—testicular cancer	6.71e-06	0.000818	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—STK11—testicular cancer	6.68e-06	0.000814	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—H2AFZ—testicular cancer	6.63e-06	0.000807	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—STK11—testicular cancer	6.59e-06	0.000803	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—KITLG—testicular cancer	6.55e-06	0.000798	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—HPGDS—testicular cancer	6.43e-06	0.000784	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—KITLG—testicular cancer	6.18e-06	0.000753	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—KITLG—testicular cancer	6.09e-06	0.000743	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—FGFR3—testicular cancer	5.29e-06	0.000645	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—HPGDS—testicular cancer	5.26e-06	0.000641	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—FGFR3—testicular cancer	5.18e-06	0.000632	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—HPGDS—testicular cancer	5.14e-06	0.000626	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—FGFR3—testicular cancer	5.1e-06	0.000622	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—H2AFZ—testicular cancer	5.07e-06	0.000618	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—STK11—testicular cancer	5.04e-06	0.000614	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—H2AFZ—testicular cancer	4.99e-06	0.000608	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—H2AFZ—testicular cancer	4.98e-06	0.000607	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—STK11—testicular cancer	4.96e-06	0.000604	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—STK11—testicular cancer	4.95e-06	0.000603	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—STK11—testicular cancer	4.94e-06	0.000603	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—FGFR3—testicular cancer	4.87e-06	0.000593	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—KIT—testicular cancer	4.86e-06	0.000592	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—HPGDS—testicular cancer	4.84e-06	0.00059	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—HPGDS—testicular cancer	4.8e-06	0.000585	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—KIT—testicular cancer	4.76e-06	0.00058	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—KIT—testicular cancer	4.68e-06	0.000571	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—STK11—testicular cancer	4.67e-06	0.000569	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—KITLG—testicular cancer	4.66e-06	0.000568	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—FGFR3—testicular cancer	4.59e-06	0.00056	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—KITLG—testicular cancer	4.59e-06	0.000559	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—KITLG—testicular cancer	4.58e-06	0.000558	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—FGFR3—testicular cancer	4.53e-06	0.000552	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—KIT—testicular cancer	4.47e-06	0.000545	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—KIT—testicular cancer	4.22e-06	0.000514	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—KIT—testicular cancer	4.16e-06	0.000507	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—HPGDS—testicular cancer	4.1e-06	0.0005	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—STK11—testicular cancer	3.82e-06	0.000466	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—STK11—testicular cancer	3.73e-06	0.000455	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—STK11—testicular cancer	3.52e-06	0.000429	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—STK11—testicular cancer	3.49e-06	0.000425	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—FGFR3—testicular cancer	3.47e-06	0.000422	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—FGFR3—testicular cancer	3.41e-06	0.000416	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—FGFR3—testicular cancer	3.4e-06	0.000415	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—KIT—testicular cancer	3.18e-06	0.000388	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—HPGDS—testicular cancer	3.16e-06	0.000386	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—KIT—testicular cancer	3.13e-06	0.000382	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—KIT—testicular cancer	3.12e-06	0.000381	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—STK11—testicular cancer	2.98e-06	0.000363	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—STK11—testicular cancer	2.3e-06	0.00028	CbGpPWpGaD
